U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H29N3O4S2
Molecular Weight 475.624
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Buloxibutid

SMILES

CCCCOC(=O)NS(=O)(=O)C1=C(C=C(CC(C)C)S1)C2=CC=C(CN3C=CN=C3)C=C2

InChI

InChIKey=XTEOJPUYZWEXFI-UHFFFAOYSA-N
InChI=1S/C23H29N3O4S2/c1-4-5-12-30-23(27)25-32(28,29)22-21(14-20(31-22)13-17(2)3)19-8-6-18(7-9-19)15-26-11-10-24-16-26/h6-11,14,16-17H,4-5,12-13,15H2,1-3H3,(H,25,27)

HIDE SMILES / InChI

Molecular Formula C23H29N3O4S2
Molecular Weight 475.624
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25560767 | https://www.ncbi.nlm.nih.gov/pubmed/19029468

Compound M24 is a selective angiotensin II AT2 receptor agonist with a Ki value of 0.4 nM for the AT2 receptor. Compound enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats, and lowers the mean arterial blood pressure in anesthetized, spontaneously hypertensive rats. In a mouse model of atherosclerosis, plaque size and stability were improved in ApoE‐/‐ mice treated with M24. Treatment with M24 resulted in decrease in scar size and reduction in markers of inflammation in a rat model of myocardial infaction.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.4 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist.
2004 Nov 18
Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?
2008 Dec 9
Compound 21, a selective agonist of angiotensin AT2 receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo.
2016 Feb
Patents

Sample Use Guides

The in vivo experiments were performed on anaesthetized nonfasted male Sprague-Dawley rats and spontaneously hypertensive rats (SHR). Compound M24 was administered intravenously at 0.003-0.3 mg/kg h. Oral PK study on rats have demonstrated absolute bioavailability of 20-30%. In the model of miocardial infarction rats were treated with M24 intraperitoneally at 0.01-0.3 mg/kg.
Route of Administration: Other
Affinity towards AT2 receptor was evaluated in a radioligand binding assays by displacement of [125I]Ang II from AT2 receptors in pig uterus membranes. Compound M24 binds to AT2 receptor with Ki of 0.4 nM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 13:28:40 UTC 2023
Edited
by admin
on Sat Dec 16 13:28:40 UTC 2023
Record UNII
RC2V4W0EYC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Buloxibutid
INN  
Official Name English
C-21
Code English
M-24
Code English
buloxibutid [INN]
Common Name English
C21
Code English
Carbamic acid, [[3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)-2-thienyl]sulfonyl]-, butyl ester
Systematic Name English
butyl [3-{4-[(1H-imidazol-1-yl)methyl]phenyl}-5-(2-methylpropyl)thiophene-2-sulfonyl]carbamate
Systematic Name English
T2 AGONIST COMPOUND 21
Common Name English
COMPOUND 21
Common Name English
Butyl [3-[4-[(1H-imidazol-1-yl)methyl]phenyl]-5-isobutylthiophen-2-yl]sulfonylcarbamate
Systematic Name English
C 21 [WHO-DD]
Common Name English
Code System Code Type Description
PUBCHEM
9804984
Created by admin on Sat Dec 16 13:28:40 UTC 2023 , Edited by admin on Sat Dec 16 13:28:40 UTC 2023
PRIMARY
SMS_ID
300000001702
Created by admin on Sat Dec 16 13:28:40 UTC 2023 , Edited by admin on Sat Dec 16 13:28:40 UTC 2023
PRIMARY
CHEBI
138409
Created by admin on Sat Dec 16 13:28:40 UTC 2023 , Edited by admin on Sat Dec 16 13:28:40 UTC 2023
PRIMARY
INN
12498
Created by admin on Sat Dec 16 13:28:40 UTC 2023 , Edited by admin on Sat Dec 16 13:28:40 UTC 2023
PRIMARY
FDA UNII
RC2V4W0EYC
Created by admin on Sat Dec 16 13:28:40 UTC 2023 , Edited by admin on Sat Dec 16 13:28:40 UTC 2023
PRIMARY
CAS
477775-14-7
Created by admin on Sat Dec 16 13:28:40 UTC 2023 , Edited by admin on Sat Dec 16 13:28:40 UTC 2023
PRIMARY
NCI_THESAURUS
C190483
Created by admin on Sat Dec 16 13:28:40 UTC 2023 , Edited by admin on Sat Dec 16 13:28:40 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
IN-VITRO
Ki
Related Record Type Details
ACTIVE MOIETY